Clinical Trials

Anatomic Stage III Breast Cancer AJCC v8

NCT04037254 2026-04-06

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

240 enrolled

Advanced Breast Cancer

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03436654 2026-03-27

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

102 enrolled

Prostatic Neoplasms

NCT06832774 2026-03-25

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

192 enrolled

Prostate Cancer Metastatic Disease

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

12 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07466498 2026-03-12

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Prostatic Neoplasms

NCT07142551 2026-03-11

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT04983095 2026-02-17

METRO

Phase NA Recruiting

118 enrolled

Prostate Cancer Metastatic

NCT05498272 2026-01-23

NePtune

32 enrolled

Prostatic Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

90 enrolled

Stage II Prostate Adenocarcinoma

NCT03809000 2025-12-30

STEEL

188 enrolled 25 charts

Prostatic Neoplasms

NCT00329043 2025-12-26

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

64 enrolled

Prostatic Neoplasms

NCT03009981 2025-12-18

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3 Completed

504 enrolled

Prostatic Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

234 enrolled

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

17 enrolled

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

110 enrolled

Oligometastatic Prostate Carcinoma

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

50 enrolled

Phase NA Active not recruiting

Prostatic Neoplasms

NCT03630666 2025-08-17

OLIGOPELVIS2

256 enrolled

Prostatic Neoplasms

NCT01420250 2025-05-15

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1 Completed

20 enrolled

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT04992026 2024-12-05

The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

130 enrolled

Prostatectomy

NCT03777982 2024-09-19

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Phase 3 Terminated

12 enrolled 5 charts

Prostatic Neoplasms

NCT00914823 2024-07-31

Kisspeptin Administration in the Adult

Phase 1 Completed

256 enrolled

Hyperprolactinemia, Hypogonadism, Polycystic Ovary Syndrome, Kallmann Syndrome

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

42 enrolled

Breast Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

345 enrolled

Prostatic Neoplasms

NCT05740488 2024-03-15

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

Phase NA Unknown

30 enrolled

Prostate Cancer With ≤10 Bone Metastases

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast Neoplasms

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1 Completed

20 enrolled

Prostatic Neoplasms

NCT00587431 2023-11-07

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

102 enrolled 8 charts

Phase 2/3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT02221999 2023-08-29

SHPD002

250 enrolled

Phase 3 Active not recruiting

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04136353 2023-07-28

DASL-HiCaP

1,100 enrolled

Prostatic Neoplasms

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

236 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT00430183 2023-02-09

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

788 enrolled 10 charts

Prostatic Neoplasms

NCT03279250 2022-08-10

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

86 enrolled 9 charts

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Prostatic Neoplasms

NCT03463252 2021-09-13

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Phase 2/3 Recruiting

224 enrolled

Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

NCT02229734 2021-06-04

FASTR-2

Prostatic Neoplasms

NCT03380806 2020-06-04

PBS

Phase 2 Unknown

100 enrolled

Prostatic Neoplasms

NCT00079001 2020-05-12

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Phase 3 Completed

645 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04182594 2019-12-02

Cardiovascular Events in GnRH Agonist vs. Antagonist

Phase 2 Unknown

80 enrolled